Huei-Jen Su Huang

Title: Innovations of Huei-Jen Su Huang

Introduction

Huei-Jen Su Huang is a notable inventor based in Rancho Santa Fe, California. She has made significant contributions to the field of biotechnology, particularly in the development of specific binding proteins. Her work focuses on antibodies that target aberrant forms of the epidermal growth factor receptor (EGFR), which is crucial in cancer research.

Latest Patents

Huei-Jen Su Huang holds a patent for "Specific binding proteins and uses thereof." This invention pertains to specific binding members, especially antibodies and their active fragments, that recognize an aberrant post-translationally modified form of EGFR. The antibodies developed do not bind to normal cells unless there is amplification of the wild-type gene. They are capable of binding to the de2-7 EGFR at a unique epitope, distinct from the junctional peptide. Notably, the novel antibody 806 is exemplified in this patent, with its VH and VL sequences detailed as SEQ ID NOs: 2 and 4, along with chimeric antibodies like ch806.

Career Highlights

Throughout her career, Huei-Jen Su Huang has worked with prominent organizations, including Abbott Laboratories Corporation and Ludwig Institute for Cancer Research Limited. Her expertise in the field has led to advancements in understanding and targeting cancer cells.

Collaborations

Huei-Jen has collaborated with esteemed colleagues such as Lloyd J Old and Terrance Grant Johns. These partnerships have further enriched her research and contributions to the scientific community.

Conclusion

Huei-Jen Su Huang's innovative work in the development of specific binding proteins has made a significant impact in cancer research. Her contributions continue to influence the field and pave the way for future advancements.